University of Notre Dame du Lac’s Alexion Pharmaceuticals ALXN Stock Holding History

University of Notre Dame du Lac’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,706	Closed	-$961K	–	60
2020 Q1	$961K	Buy	10,706 +1,681	+19%	+$165K	0.3%	43
2019 Q4	$976K	Buy	9,025 +861	+11%	+$92.1K	0.31%	44
2019 Q3	$800K	Sell	8,164 -20,018	-71%	-$2.26M	0.24%	50
2019 Q2	$3.69M	Sell	28,182 -33,336	-54%	-$4.3M	0.84%	48
2019 Q1	$8.32M	Buy	61,518 +21,513	+54%	+$2.68M	1.86%	25
2018 Q4	$3.9M	Sell	40,005 -6,439	-14%	-$761K	0.94%	43
2018 Q3	$6.46M	Buy	46,444 +1,213	+3%	+$152K	1.2%	41
2018 Q2	$5.62M	Sell	45,231 -437	-1%	-$51.1K	1.09%	42
2018 Q1	$5.09M	Sell	45,668 -25,769	-36%	-$3.08M	0.95%	45
2017 Q4	$8.54M	Buy	71,437 +33,511	+88%	+$4.08M	1.77%	11
2017 Q3	$5.32M	Sell	37,926 -2,906	-7%	-$395K	1.48%	18
2017 Q2	$4.97M	Buy	40,832 +2,127	+5%	+$248K	1.47%	12
2017 Q1	$4.69M	Buy	+38,705	New	+$4.99M	1.17%	47

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

University of Notre Dame du Lac's ALXN Position: Q2 2020 in Review

University of Notre Dame du Lac sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 10,706 shares — an estimated $961K sold.

University of Notre Dame du Lac first reported a position in ALXN in Q1 2017 and held it in 13 quarters. The position peaked at $8.54M in Q4 2017. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

University of Notre Dame du Lac reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
University of Notre Dame du Lac sold 10,706 Alexion Pharmaceuticals shares in Q2 2020, an estimated $961K.
University of Notre Dame du Lac first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 13 quarters.
University of Notre Dame du Lac's Alexion Pharmaceuticals position peaked at $8.54M in Q4 2017.
706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on University of Notre Dame du Lac's 13F filing for Q2 2020, filed 14 Aug 2020.